Lung adenocarcinoma (LUAD), as the most common histological subtype of primary lung cancer, is characterized by rapid proliferation and easy metastasis. Although many biomarkers for LUAD have been identified, their specificity and sensitivity remain unsatisfactory. Abnormal lipid metabolism plays a major role in the occurrence and development of tumors. Endothelial lipase (EL) is a key enzyme in high density lipoprotein (HDL) metabolism, and its encoding gene is endothelial lipase gene (LIPG). In present study, bioinformatics and clinical sample data were used to explore the relationship between LIPG and clinical characteristics and prognosis of LUAD patients, and the possible mechanism of LIPG in LUAD was also explored. The results showed that LIPG is associated with poor prognosis in LUAD patients, and may influence the occurrence and development of tumors by participating in lipid metabolism and immune signaling pathways of LUAD. The present study may provide new evidence for individualized precision therapy for LUAD patients.
